Pancreatic Cancer Research

ResearcherComprehensive Cancer Center ViennaActive in the last 2 years

Klaus Sahora

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3068-5050; OpenAlex author ID A5074707947. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: none · 2014: 3 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers

Papers 19

  1. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  2. Standardized Approach to Superior Mesenteric Artery Resection for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3791/68465↗
  3. Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment. Co-author DOI 10.1016/j.jviscsurg.2023.06.004↗
  4. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis. Co-author DOI 10.1097/js9.0000000000000792↗
  5. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  6. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  7. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  8. [Surgery for periampullary pancreatic cancer]. Co-author DOI 10.1007/s00104-021-01462-1↗
  9. Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. Co-author DOI 10.1007/s11605-019-04187-z↗
  10. The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. Co-author DOI 10.1245/s10434-019-08161-6↗
  11. Correction to: The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. Co-author DOI 10.1245/s10434-020-09010-7↗
  12. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0215915↗
  13. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. Co-author DOI 10.1016/j.ejso.2016.03.011↗
  14. Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. First author DOI 10.1007/s00268-013-2283-3↗
  15. Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/apm.12194↗
  16. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. Co-author PMID 24778046↗
  17. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. Co-author DOI 10.1007/s00268-011-1113-8↗
  18. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Co-author DOI 10.1016/j.surg.2010.07.048↗
  19. Gadobenate dimeglumine-enhanced 3.0-T MR imaging versus multiphasic 64-detector row CT: prospective evaluation in patients suspected of having pancreatic cance… Co-author DOI 10.1148/radiol.11101189↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martin Schindl · 14 shared papers, 2011–2025 · strength 1.81
  2. Oliver Strobel · 6 shared papers, 2021–2025 · strength 1.33
  3. Carl-Stephan Leonhardt · 5 shared papers, 2023–2025 · strength 1.16
  4. Ulla Klaiber · 5 shared papers, 2021–2025 · strength 1.10
  5. Thomas P. Hank · 5 shared papers, 2021–2025 · strength 0.96
  6. Gerd Jomrich · 6 shared papers, 2019–2024 · strength 0.88
  7. Elisabeth S. Gruber · 5 shared papers, 2019–2024 · strength 0.70
  8. Michael Gnant · 7 shared papers, 2011–2020 · strength 0.62
  9. Gerald W. Prager · 3 shared papers, 2023–2025 · strength 0.58
  10. Andrew Louis Warshaw · 3 shared papers, 2023–2025 · strength 0.57
  11. Motaz Qadan · 3 shared papers, 2023–2025 · strength 0.57
  12. Keith D. Lillemoe · 3 shared papers, 2023–2025 · strength 0.57
  13. Carlos F. Fernandez-del Castillo · 2 shared papers, 2023–2025 · strength 0.39
  14. Cristina Rosa Ferrone · 2 shared papers, 2023–2024 · strength 0.34
  15. Cristina R. Ferrone · 1 shared paper, 2025 · strength 0.23
  16. Caroline Sophie Verbeke · 1 shared paper, 2024 · strength 0.22
  17. Carlos Fernández-del Castillo · 1 shared paper, 2024 · strength 0.18
  18. Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
  19. Raëf Abdallah · 1 shared paper, 2023 · strength 0.12
  20. Jin‐Young Jang · 1 shared paper, 2023 · strength 0.12
  21. Giuseppe Malleo · 1 shared paper, 2023 · strength 0.12
  22. Gregory C. Wilson · 1 shared paper, 2023 · strength 0.12
  23. Ryan K. Schmocker · 1 shared paper, 2023 · strength 0.12
  24. Jin Peng He · 1 shared paper, 2023 · strength 0.12
  25. Sarah Maloney · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.